AV001-004, AV-001 for Pneumonia

Internal Medicine Infectious Disease Pulmonology Heart and Vascular COVID-19 Influenza Respiratory Distress Syndrome Bacterial Infectious Diseases Lung Disease Infectious Disease Vascular Disease Adult Subjects

A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be recruited from up to 25 participating institutions/hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).

IM027068 BMS-986278 for Idiopathic Lung Fibrosis

Internal Medicine Pulmonology Lung Disease Adult Subjects

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

DAS181-3-01, DAS181, for Parainfluenza

Cancer Internal Medicine Infectious Disease Pulmonology COVID-19 Airway Disease Infectious Disease Pediatric Subjects Adult Subjects

This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.

It also contains a sub-study to enroll patients with severe COVID-19.

AR-DEX-22-01, Dexpramipexole for EOS asthma EXHALE

Internal Medicine Pulmonology Airway Disease Adult Subjects

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.

SPR720-202, SPR720, for MAC Pulmonary Disease

Internal Medicine Pulmonology Lung Disease Adult Subjects

The purpose of the study is to evaluate

1. The microbiological response and clinical efficacy of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD).
2. The safety and tolerability of SPR720 in a participants population with NTM- PD
3. The pharmacokinetic (PK) of SPR719, active moiety, following orally (po) administered prodrug SPR720 in a participant population with NTM-PD.

MK5475-013

Internal Medicine Pulmonology Heart and Vascular Pulmonary Hypertension Airway Disease Heart Disease Lung Disease Adult Subjects Female Subjects Male Subjects

Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.

Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease

Internal Medicine Pulmonology Airway Disease Lung Disease Adult Subjects

The purpose of this study is to compare the efficacy and safety of a real time video telehealth pulmonary rehabilitation intervention with standard of care in patients hospitalized for an exacerbation of chronic obstructive pulmonary disease (COPD) to determine the impact on hospital readmissions and respiratory morbidity, and to investigate the cost-effectiveness of the intervention.